Trial Profile
A Multi-center, Open-label, Cohort Study to Assess Feasibility, Acute Safety, Tolerability and Pharmacokinetics of 4 Dose Regimens of Continuous Intrathecal ATI355 Infusion and Two Regimen of Repeated Intrathecal Bolus Injections in Acute Spinal Cord Injury Paraplegic and Tetraplegic Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 May 2014
Price :
$35
*
At a glance
- Drugs ATI 355 (Primary)
- Indications Spinal cord injuries
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis
- 15 May 2014 New trial record